Sudarshan Pharma Industries Ltd Stock Price Today (NSE: SUDARSHAN)

Sudarshan Pharma Industries Ltd

34.203.69 (9.74%)
Market Closed

Fundamental Score

...

Sudarshan Pharma Industries Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Sudarshan Pharma Industries Ltd share price today is 34.20, down 9.74% on NSE/BSE as of 4 August 2026. Sudarshan Pharma Industries Ltd (SUDARSHAN) is a Small-cap company in the Specialty Chemicals sector with a market capitalisation of 1.00K (Cr). The 52-week high for SUDARSHAN share price is 42.79 and the 52-week low is 18.50. At a P/E ratio of 42.99x, SUDARSHAN is currently trading above its industry average P/E of 31.95x. The company has a Return on Equity (ROE) of 16.26% and a debt-to-equity ratio of 1.84.

Sudarshan Pharma Industries Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
42.79
Low
34.20
Volume
4.1L
Change
-1.30%

Sudarshan Pharma Industries Ltd share price chart: -1.30% return over the past month. 52-week high ₹42.79, 52-week low ₹18.50.

Sudarshan Pharma Industries Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
38.3938.3936.0036.002.64L (Cr)
38.0038.0036.8837.8948.00K (Cr)
39.4940.5538.5040.426.28L (Cr)
41.9841.9839.3639.721.40L (Cr)
40.8042.4839.7341.434.04L (Cr)
41.0442.7941.0342.3180.00K (Cr)
39.1542.0038.3041.041.76L (Cr)
41.6441.6440.0040.0084.00K (Cr)
41.5041.8940.3140.3148.00K (Cr)
40.4942.0040.4941.966.76L (Cr)

Sudarshan Pharma Industries Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
38.3938.3936.0036.00-6.23%
37.2142.7936.0037.89+1.83%
35.0540.4132.6937.51+7.02%
31.4036.9527.7535.05+11.62%
24.9032.4824.7530.26+21.53%
27.0427.7921.9424.24-10.36%
20.0028.4019.3628.06+40.30%
27.4228.3918.5019.70-28.15%
25.0830.0021.6227.55+9.85%
27.1029.0022.8025.13-7.27%
25.5030.0622.3327.03+6.00%
33.2533.4025.4826.00-21.80%

Returns & Performance

Average

Return on Equity (ROE)

16.26%

Profit generated per ₹1 of shareholder equity

Average

Return on Capital (ROCE)

15.13%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

5.62%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Sudarshan Pharma Industries Ltd Valuation Check

Poor

Price to Earnings (P/E)

42.99x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

31.95x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

57.39%

% shares held by company founders/management

Good

FII Holding

19.95%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

24.91%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

36.72%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

29.46%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

28.20%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

54.23%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

1.84x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

2.19x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-66.54 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Sudarshan Pharma Industries Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of SUDARSHAN across key market metrics for learning purposes.

Positive Indicators

9 factors identified

Strong Return on Equity (16.26%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (15.13%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Robust Profit Growth (24.91%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (36.72%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (29.46% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Excellent EPS Growth (28.20% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (54.23% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Balanced Promoter Holding (57.39%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

5 factors identified

Premium Valuation Risk (P/E: 42.99x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Elevated Debt Levels (D/E: 1.84)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.

Weak Interest Coverage (2.19x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Negative Free Cash Flow (₹-66.54 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Sudarshan Pharma Industries Ltd vs Specialty Chemicals Peers

Peer Comparison - Specialty Chemicals

Compare Sudarshan Pharma Industries Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
59.3/100
34
₹1001.62
43.0
Average
16.26%
Good
15.13%
Good
1.8
Average
54.23%
Excellent
29.46%
Excellent
0.00%
65.3/100
1611
₹159989.82
65.0
Average
23.92%
Excellent
31.02%
Excellent
0.0
Excellent
16.69%
Excellent
14.89%
Good
0.73%
42.9/100
4367
₹45440.05
77.3
Average
7.78%
Poor
9.86%
Poor
0.3
Excellent
36.34%
Excellent
13.52%
Good
0.07%
62.7/100
7568
₹39027.62
58.4
Average
20.26%
Excellent
21.37%
Excellent
0.3
Excellent
22.16%
Excellent
22.95%
Excellent
0.20%
32.8/100
1662
₹23159.08
41.4
Average
9.97%
Poor
11.49%
Average
0.3
Excellent
-6.33%
Poor
12.59%
Good
0.44%
36.3/100
1540
₹19624.13
86.7
Average
9.66%
Poor
11.92%
Average
0.2
Excellent
0.00%
38.7/100
489
₹18171.13
44.1
Average
7.13%
Poor
6.85%
Poor
0.8
Good
-4.67%
Poor
12.96%
Good
0.20%
Atul Ltd...
ATUL500027
58.2/100
6737
₹18051.49
26.6
Average
11.49%
Average
14.90%
Average
0.0
Excellent
1.26%
Average
10.95%
Good
0.49%
52.2/100
3634
₹16002.35
38.4
Average
10.92%
Average
14.68%
Average
0.0
Excellent
7.67%
Good
9.41%
Good
0.68%
62.09999999999999/100
4817
₹15713.17
38.1
Average
16.61%
Good
21.47%
Excellent
0.0
Excellent
27.91%
Excellent
15.86%
Excellent
0.21%
33.3/100
1208
₹14449.70
84.9
Average
5.50%
Poor
7.36%
Poor
0.6
Good
19.29%
Excellent
23.88%
Excellent
0.06%

Sudarshan Pharma Industries Ltd PE Ratio History

Historical price-to-earnings ratio for SUDARSHAN — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20240.47₹44.5994.9x
FY 20230.55₹8.1314.8x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Sudarshan Pharma Industries Ltd Dividend History

Annual cash dividends paid by SUDARSHAN — dividend yield N/A

Financial YearDividends Paid (₹ Cr)
FY 20240.72 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Sudarshan Pharma Industries Ltd Quarterly Performance

Latest quarterly metrics for SUDARSHAN — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

36.72%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

24.91%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

29.46%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

54.23%

Compounded annual net profit growth over 5 years

Sudarshan Pharma Industries Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for SUDARSHAN — calculated from daily price history

45RSI 14
Neutral — RSI 45

Momentum is balanced — neither overbought nor oversold.

SMA 50
37
▼ Price below SMA 50 — Short-term bearish
SMA 200
29
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
352K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Sudarshan Pharma Industries Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Sudarshan Pharma Industries Ltd (SUDARSHAN) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Sudarshan Pharma Industries Ltd

About SUDARSHAN (Sudarshan Pharma Industries Ltd)

Sudarshan Pharma Industries Ltd is a dynamic force within the specialty chemicals sector, crafting a diverse portfolio of high-quality chemical solutions for a multitude of industr...ies. With a strong foundation built on innovation and customer-centricity, Sudarshan specializes in the creation of advanced intermediates critical for the pharmaceutical and agrochemical sectors. Beyond these key areas, the company extends its expertise to providing bespoke chemical solutions for the coating, construction, and various other industrial applications, tailoring products to meet specific and evolving needs. Sudarshan’s commitment to research and development ensures it remains at the forefront of chemical innovation, constantly exploring new avenues to deliver enhanced performance and value to its clients. The core strength of Sudarshan Pharma Industries lies in its comprehensive manufacturing capabilities, allowing for the production of both Active Pharmaceutical Ingredients (APIs) and essential vitamins. This vertical integration provides significant advantages in terms of quality control, cost efficiency, and supply chain management. Further diversifying its offerings, Sudarshan also produces fine chemicals and solvents, serving as a reliable partner for industries requiring high-purity materials. The company's unwavering focus on adherence to stringent quality standards and regulatory compliance reinforces its position as a trusted supplier of critical chemical components. Sudarshan Pharma Industries’ expansive product range caters to a wide array of specialized applications. This includes the development and manufacturing of specialized materials for leather processing, oil field operations, and lubricant formulations. The company also provides key chemicals for the creation of high-performance paints and coatings, as well as essential additives for the paper industry. Furthermore, Sudarshan manufactures ingredients used in personal care products, alongside specialized chemicals tailored for food coloring applications. By consistently providing innovative and reliable solutions, Sudarshan Pharma Industries remains a vital partner to businesses across numerous sectors, driving growth and enabling advancement.

Company Details

Symbol:SUDARSHAN
Industry:Specialty Chemicals
Sector:Specialty Chemicals

Key Leadership

Mr. Hemal Vasantrai Mehta
Founder, Chairman & MD
Mr. Sachin Vasantrai Mehta
Founder, Joint MD, CFO & Director
Mr. Nirav Kishor Shah
Company Secretary & Compliance Officer

SUDARSHAN Share Price: Frequently Asked Questions

What is the current share price of Sudarshan Pharma Industries Ltd?

Sudarshan Pharma Industries Ltd (SUDARSHAN) trades at ₹34.20 on NSE and BSE. Market cap ₹1.00K (Cr). Educational data only.

What is the P/E ratio of Sudarshan Pharma Industries Ltd?

Sudarshan Pharma Industries Ltd has a P/E of 42.99x vs industry average 31.95x.

What is the Bull Run score for Sudarshan Pharma Industries Ltd?

Sudarshan Pharma Industries Ltd has a Bull Run score of 59.3/100 based on 25+ financial parameters.

Does Sudarshan Pharma Industries Ltd pay dividends?

Sudarshan Pharma Industries Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Sudarshan Pharma Industries Ltd?

Sudarshan Pharma Industries Ltd has ROE of 16.26%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Sudarshan Pharma Industries Ltd?

Sudarshan Pharma Industries Ltd has debt-to-equity of 1.84.

Is Sudarshan Pharma Industries Ltd a good investment?

Bull Run gives Sudarshan Pharma Industries Ltd a score of 59.3/100. This is not investment advice — consult a SEBI-registered advisor.